232 related articles for article (PubMed ID: 22082361)
1. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
[TBL] [Abstract][Full Text] [Related]
2. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
3. Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes.
Grcević D; Kusec R; Kovacić N; Lukić A; Lukić IK; Ivcević S; Nemet D; Seiwerth RS; Ostojić SK; Croucher PI; Marusić A
Leuk Res; 2010 Jun; 34(6):742-51. PubMed ID: 19926132
[TBL] [Abstract][Full Text] [Related]
4. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
[TBL] [Abstract][Full Text] [Related]
5. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.
Vincent C; Findlay DM; Welldon KJ; Wijenayaka AR; Zheng TS; Haynes DR; Fazzalari NL; Evdokiou A; Atkins GJ
J Bone Miner Res; 2009 Aug; 24(8):1434-49. PubMed ID: 19292615
[TBL] [Abstract][Full Text] [Related]
6. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.
Silvestris F; Cafforio P; De Matteo M; Calvani N; Frassanito MA; Dammacco F
Clin Cancer Res; 2008 Oct; 14(19):6081-91. PubMed ID: 18829486
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.
Wang XT; He YC; Zhou SY; Jiang JZ; Huang YM; Liang YZ; Lai YR
Leuk Res; 2014 May; 38(5):525-31. PubMed ID: 24656650
[TBL] [Abstract][Full Text] [Related]
9. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
10. Characterization of in vitro growth of multiple myeloma cells.
Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
[TBL] [Abstract][Full Text] [Related]
11. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E; Christoulas D; Katodritou E; Bratengeier C; Gkotzamanidou M; Michalis E; Delimpasi S; Pouli A; Meletis J; Kastritis E; Zervas K; Dimopoulos MA
Int J Cancer; 2012 Sep; 131(6):1466-71. PubMed ID: 22052418
[TBL] [Abstract][Full Text] [Related]
12. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
16. Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.
Pérez-Simón JA; Valverde B; Martínez A; Tabernero D; Almeida J; Gutierrez N; San Miguel JF; Orfao A
Cytometry; 1999 Feb; 38(1):24-9. PubMed ID: 10088973
[TBL] [Abstract][Full Text] [Related]
17. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
20. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]